| Toxin pattern number | Pattern | Percentage of isolates | Resistance category | Distribution among sources | ||||||||||||||
| sea | seb | sec | see | seg | ||||||||||||||
| MDR (n) | NMDR (n) | Clinical | Non clinical | |||||||||||||||
| D.F | W | Bl | U | B | A | Sp | T.S | En | ||||||||||
| T1 | + |
|
|
|
| 25% | 7 | 18 | 3 | 5 | 7 | 2 | 1 | 3 | 3 | 1 | 0 | |
| T2 |
| + |
|
|
| 9% | 2 | 7 | 1 | 3 | 0 | 1 | 0 | 1 | 0 | 0 | 3 | |
| T3 |
|
| + |
|
| 2% | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | |
| T4 |
|
|
| + |
| 3% | 1 | 2 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | |
| T5 | + | + |
|
|
| 11% | 7 | 4 | 3 | 3 | 0 | 1 | 3 | 1 | 0 | 0 | 0 | |
| T6 | + |
| + |
|
| 10% | 4 | 6 | 4 | 3 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | |
| T7 | + |
|
| + |
| 9% | 3 | 6 | 0 | 1 | 3 | 2 | 2 | 0 | 1 | 0 | 0 | |
| T8 |
| + | + |
|
| 2% | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | |
| T9 |
| + |
| + |
| 4% | 1 | 3 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | |
| T10 |
| + |
|
| + | 2% | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | |
| T11 | + | + | + |
|
| 5% | 1 | 4 | 4 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | |
| T12 | + | + |
| + |
| 1% | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| T13 | + | + |
|
| + | 1% | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | |
| T14 | + |
| + | + |
| 1% | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | |
| T15 | + | + | + |
| + | 2% | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | |
| T16 | + | + | + | + |
| 1% | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | |
| T17 |
|
|
|
|
| 12% | 3 | 9 | 3 | 1 | 0 | 2 | 1 | 0 | 1 | 2 | 2 | |